Chengdu Kanghua Biological Products
Chengdu Kanghua Biological Products Co., Ltd. engages in the research, development, production, sale, and technical service of biological products in China. It offers group ACYW135 meningococcal polysaccharide vaccines; and freeze-dried human diploid cell rabies vaccines. The company also develops seasonal influenza vaccines. In addition, it exports its products. Chengdu Kanghua Biological Produc… Read more
Chengdu Kanghua Biological Products (300841) - Net Assets
Latest net assets as of September 2025: CN¥3.51 Billion CNY
Based on the latest financial reports, Chengdu Kanghua Biological Products (300841) has net assets worth CN¥3.51 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥3.94 Billion) and total liabilities (CN¥430.82 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥3.51 Billion |
| % of Total Assets | 89.06% |
| Annual Growth Rate | N/A |
| 5-Year Change | 74.61% |
| 10-Year Change | N/A |
| Growth Volatility | 78.65 |
Chengdu Kanghua Biological Products - Net Assets Trend (2015–2024)
This chart illustrates how Chengdu Kanghua Biological Products's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Chengdu Kanghua Biological Products (2015–2024)
The table below shows the annual net assets of Chengdu Kanghua Biological Products from 2015 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥3.45 Billion | -1.89% |
| 2023-12-31 | CN¥3.51 Billion | +14.25% |
| 2022-12-31 | CN¥3.08 Billion | +15.18% |
| 2021-12-31 | CN¥2.67 Billion | +35.24% |
| 2020-12-31 | CN¥1.97 Billion | +243.59% |
| 2019-12-31 | CN¥574.65 Million | +56.28% |
| 2018-12-31 | CN¥367.70 Million | +95.20% |
| 2017-12-31 | CN¥188.37 Million | +295.78% |
| 2016-12-31 | CN¥-96.21 Million | +6.47% |
| 2015-12-31 | CN¥-102.87 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Chengdu Kanghua Biological Products's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 250195639300.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥2.39 Billion | 69.30% |
| Common Stock | CN¥132.95 Million | 3.86% |
| Other Components | CN¥925.48 Million | 26.84% |
| Total Equity | CN¥3.45 Billion | 100.00% |
Chengdu Kanghua Biological Products Competitors by Market Cap
The table below lists competitors of Chengdu Kanghua Biological Products ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Huachangda Intelligent Equipment Group Co Ltd
SHE:300278
|
$934.20 Million |
|
Beijing SuperMap Software Co Ltd
SHE:300036
|
$934.64 Million |
|
Seino Holdings Co. Ltd
F:XSE
|
$934.65 Million |
|
New World Development Company Limited
PINK:NWWDF
|
$934.90 Million |
|
Cadre Holdings Inc
NYSE:CDRE
|
$934.06 Million |
|
Attendo AB (publ)
ST:ATT
|
$933.99 Million |
|
Navios Maritime Partners LP Unit
NYSE:NMM
|
$933.97 Million |
|
Lifestyle Communities Limited
PINK:LCOMF
|
$933.84 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Chengdu Kanghua Biological Products's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 3,514,051,747 to 3,447,508,696, a change of -66,543,051 (-1.9%).
- Net income of 398,651,927 contributed positively to equity growth.
- Dividend payments of 267,827,351 reduced retained earnings.
- Share repurchases of 199,997,626 reduced equity.
- Other comprehensive income decreased equity by 133,533,334.
- Other factors increased equity by 136,163,333.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥398.65 Million | +11.56% |
| Dividends Paid | CN¥267.83 Million | -7.77% |
| Share Repurchases | CN¥200.00 Million | -5.8% |
| Other Comprehensive Income | CN¥-133.53 Million | -3.87% |
| Other Changes | CN¥136.16 Million | +3.95% |
| Total Change | CN¥- | -1.89% |
Book Value vs Market Value Analysis
This analysis compares Chengdu Kanghua Biological Products's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.31x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | CN¥-0.76 | CN¥60.51 | x |
| 2016-12-31 | CN¥-0.71 | CN¥60.51 | x |
| 2017-12-31 | CN¥1.40 | CN¥60.51 | x |
| 2018-12-31 | CN¥3.67 | CN¥60.51 | x |
| 2019-12-31 | CN¥4.26 | CN¥60.51 | x |
| 2020-12-31 | CN¥14.63 | CN¥60.51 | x |
| 2021-12-31 | CN¥19.78 | CN¥60.51 | x |
| 2022-12-31 | CN¥22.96 | CN¥60.51 | x |
| 2023-12-31 | CN¥26.27 | CN¥60.51 | x |
| 2024-12-31 | CN¥26.19 | CN¥60.51 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Chengdu Kanghua Biological Products utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 11.56%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 27.84%
- • Asset Turnover: 0.36x
- • Equity Multiplier: 1.17x
- Recent ROE (11.56%) is below the historical average (21.12%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | 0.00% | 16.47% | 0.42x | 0.00x | CN¥21.99 Million |
| 2016 | 0.00% | 7.17% | 0.46x | 0.00x | CN¥16.28 Million |
| 2017 | 39.53% | 28.43% | 0.95x | 1.46x | CN¥55.62 Million |
| 2018 | 41.92% | 27.55% | 1.15x | 1.32x | CN¥117.37 Million |
| 2019 | 32.49% | 33.66% | 0.80x | 1.20x | CN¥129.22 Million |
| 2020 | 20.67% | 39.29% | 0.48x | 1.09x | CN¥210.60 Million |
| 2021 | 31.06% | 64.18% | 0.43x | 1.13x | CN¥562.45 Million |
| 2022 | 19.45% | 41.34% | 0.39x | 1.21x | CN¥290.50 Million |
| 2023 | 14.49% | 32.28% | 0.37x | 1.20x | CN¥157.81 Million |
| 2024 | 11.56% | 27.84% | 0.36x | 1.17x | CN¥53.90 Million |
Industry Comparison
This section compares Chengdu Kanghua Biological Products's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,043,310,248
- Average return on equity (ROE) among peers: 14.20%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Chengdu Kanghua Biological Products (300841) | CN¥3.51 Billion | 0.00% | 0.12x | $934.13 Million |
| Shenzhen CAU Technology Co Ltd (000004) | $124.02 Million | 4.50% | 1.13x | $80.66 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $525.49 Million | 14.76% | 1.41x | $1.02 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $174.34 Million | 36.11% | 1.61x | $288.51 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $642.80 Million | -4.58% | 0.44x | $244.62 Million |
| Chengzhi Shareholding Co Ltd (000990) | $1.69 Billion | 3.06% | 0.97x | $850.04 Million |
| Hualan Biological EngineeringInc (002007) | $1.86 Billion | 32.78% | 0.08x | $2.00 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $2.09 Billion | 4.42% | 0.71x | $784.18 Million |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $831.21 Million | 22.32% | 0.12x | $3.76 Billion |
| Baolingbao Biology Co Ltd (002286) | $2.04 Billion | 5.44% | 0.31x | $398.99 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $456.61 Million | 23.20% | 0.29x | $347.95 Million |